Q2 2023
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXRX | New | Recursion Pharmaceuticals, Inc. | $77,730,340 | – | 10,405,668 | – | 100.00% | – |
Q4 2022
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | Babylon Holdings Ltd | $0 | – | -54,942,568 | – | -21.74% | – | |
| TDOC | Exit | Teladoc Health, Inc. | $0 | – | -3,683,668 | – | -78.26% | – |
Q2 2022
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TDOC | New | Teladoc Health, Inc. | $122,335,000 | – | 3,683,668 | – | 69.48% | – |
| New | Babylon Holdings Ltd | $53,734,000 | – | 54,942,568 | – | 30.52% | – |